Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 6,250 shares of the company's stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $28.56, for a total value of $178,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Benjamin Hohl also recently made the following trade(s):
- On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $24,420.00.
- On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total value of $281,097.18.
- On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total value of $34,937.70.
- On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.27, for a total transaction of $103,147.50.
- On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.33, for a total transaction of $50,660.00.
- On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.54, for a total transaction of $95,795.00.
Enliven Therapeutics Stock Down 0.5 %
The Crypto That’s Making Wall Street Sweat
From Crypto 101 Media | Ad
The Crypto Wall Street Is Desperate to Hide
It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.
Click here to discover our #1 crypto for the market right now – poised for massive growth
Enliven Therapeutics stock opened at $28.39 on Thursday. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $30.03. The company has a market cap of $1.34 billion, a P/E ratio of -14.71 and a beta of 1.10. The business has a 50-day simple moving average of $24.95 and a two-hundred day simple moving average of $23.13.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.17. Research analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 EPS for the current fiscal year.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a "buy" rating and set a $37.00 target price on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.
View Our Latest Analysis on ELVN
Institutional Investors Weigh In On Enliven Therapeutics
A number of hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. lifted its position in Enliven Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company's stock valued at $232,000 after purchasing an additional 3,559 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Enliven Therapeutics in the third quarter worth about $256,000. The Manufacturers Life Insurance Company bought a new position in shares of Enliven Therapeutics in the second quarter worth about $322,000. Marshall Wace LLP purchased a new position in shares of Enliven Therapeutics during the 2nd quarter valued at about $4,489,000. Finally, First Turn Management LLC bought a new position in shares of Enliven Therapeutics during the 2nd quarter valued at approximately $9,657,000. Institutional investors own 95.08% of the company's stock.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
